AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ENTA · NASDAQ · Biotechnology

Enanta Pharmaceuticals

Develops oral RSV antivirals and immunology drugs funded by AbbVie HCV royalties.

$13.60

After-hours close−0.03 (−0.22%)

At close$13.63(−1.23%)

Something off on this page? Send us feedback.

Profile

Enanta Pharmaceuticals, Inc.ENTAHealth Care

Develops small-molecule drugs in virology and immunology while receiving royalties tied to AbbVie's MAVYRET/MAVIRET HCV regimen. The pipeline is wholly owned, led by RSV antivirals and oral type two immunology programs.

Discovers and develops oral small-molecule drugs for virology and immunology. Current revenue comes from royalties on worldwide AbbVie sales of MAVYRET/MAVIRET, where Enanta-discovered glecaprevir is paired with pibrentasvir.

Wholly owned development work centers on RSV antivirals, including zelicapavir and EDP-323, plus oral immunology programs aimed at KIT, STAT6, and MRGPRX2. Watertown-based operations are reported as one segment and remain concentrated in research rather than commercial sales.

The business depends on AbbVie HCV sales for royalty revenue, clinical and regulatory progress in RSV and immunology, and outcomes in patent litigation involving Pfizer's Paxlovid.

Company facts

CEOJay R. Luly, Ph.D.

ListedMar 21, 2013

ExchangeNASDAQ

HeadquartersWatertown, MA

CountryUnited States

Employees120

CIK0001177648

ISINUS29251M1062

Key statistics

Market cap$395.5M

EPS (ttm)−$2.41

P/E (ttm)−5.64

ROE-61.8%

P/B3.91

P/S6.06

Dividend yield—

Beta0.97vs XLV 0.37

Year to date −5.5% · Average volume (30d) 194.7K

Analysts

Price target, next 12 months$20.00+47.1%Median of 19 analysts · vs the Aug 28 close

ConsensusBuy14 of 19 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $13.60

High$20.00+47.1%

Median$20.00+47.1%

Low$20.00+47.1%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Jun 23, 2026	H.C. Wainwright	Reiterate		Buy	$56	$20
Oct 1, 2025	Jefferies	Upgrade	Hold	Buy		$20

Earnings

EPS

Estimate−$0.77

ReportedDue Nov 16, 2026

Revenue

Estimate$15.7M

ReportedDue Nov 16, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 10, 2026Q3 FY26	−$0.51	−$0.67	−31.5%	$16.8M	$14.4M	−14.3%	−2.10%
May 11, 2026Q2 FY26	−$0.46	−$0.45	+2.2%	$17.0M	$17.2M	+0.8%	−6.02%
Feb 9, 2026Q1 FY26	−$0.54	−$0.42	+22.2%	$15.9M	$18.6M	+17.0%	+2.17%
Nov 17, 2025Q4 FY25	−$1.13	−$0.87	+23.0%	$16.0M	$15.1M	−5.3%	−3.59%

View details

Financial highlights

	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26
Revenue	$14.9M	$18.3M	$15.1M	$18.6M	$17.2M	$14.4M
Gross profit	$14.9M	$18.3M	$15.1M	$18.6M	$16.0M	$14.4M
Operating income	−$24.5M	−$18.9M	−$18.4M	−$11.3M	−$11.9M	−$17.2M
Net income	−$22.6M	−$18.3M	−$18.7M	−$11.9M	−$13.1M	−$19.5M
Diluted EPS	−$1.06	−$0.86	−$0.87	−$0.42	−$0.45	−$0.67
Gross margin	100.0%	100.0%	100.0%	100.0%	93.0%	100.0%
Operating margin	-164.3%	-103.2%	-121.6%	-60.5%	-69.1%	-120.0%

Fiscal years (4-quarter sums)FY21 $97.1M · FY22 $86.2M · FY23 $79.2M · FY24 $67.6M · FY25 $65.3M

Revenue by product · Q3 FY26

Royalty$14.4M · 100%

Balance sheet, Jun 30, 2026Cash & short-term investments $189.5M · Total debt $55.7M · Total assets $296.9M · Shareholders' equity $101.1M

Dividends

No dividends on record.

Ownership

Institutions 94.80%27.57M sharesInsiders 4.67%1.36M sharesOther 0.53%153.6K shares

Shares outstanding 29.08M · Float 27.60M · 94.9% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Jupiter Topco LLC	3.65M	12.57%	13F	Aug 14, 2026
Janus Henderson Group PLC	3.49M	12.10%	13G	Nov 7, 2025
BlackRock, Inc.	3.24M	11.16%	13F	Aug 7, 2026
Krensavage Asset Management, LLC	2.87M	9.86%	13F	Aug 14, 2026
Farallon Capital Management LLC	2.42M	8.32%	13F	Aug 14, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Dec 5, 2025	Jay R. Luly	director, officer: President and CEO	−4,743	$14.23
Dec 5, 2025	Yat Sun Or	officer: Chief Scientific Officer	−2,390	$14.23
Dec 5, 2025	Tara Lynn Kieffer	officer: Chief Product Strategy Officer	−2,106	$14.23
Dec 5, 2025	Brendan Luu	officer: Chief Business Officer	−1,394	$14.23
Dec 5, 2025	Scott T. Rottinghaus	officer: Chief Medical Officer	−798	$14.23